Viking Therapeutics (VKTX)
(Delayed Data from NSDQ)
$64.63 USD
+0.28 (0.44%)
Updated Aug 23, 2024 04:00 PM ET
After-Market: $64.52 -0.11 (-0.17%) 7:58 PM ET
3-Hold of 5 3
C Value D Growth C Momentum D VGM
Cash flow Statements
Fiscal Year End for Viking Therapeutics, Inc falls in the month of December.
All data in Millions except Per Share data.
Cash Flow From Operations, Investments & Financial Activities
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
---|---|---|---|---|---|
Cash Flow From Operations, Investments & Financial Activities |
|||||
Net Income (Loss) | -85.90 | -68.87 | -54.99 | -39.50 | -25.78 |
Depreciation/Amortization & Depletion | -7.82 | 1.57 | 4.22 | 4.19 | 1.02 |
Net Change from Assets/Liabilities | 3.55 | 10.19 | -2.93 | 7.72 | -3.78 |
Net Cash from Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Operating Activities | 16.79 | 8.71 | 6.11 | 5.81 | 3.79 |
Net Cash From Operating Activities | -73.38 | -48.40 | -47.59 | -21.78 | -24.75 |
Property & Equipment | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Acquisition/ Disposition of Subsidiaries | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Investments | -179.09 | 54.75 | 37.96 | 41.57 | 7.46 |
Other Investing Activities | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Net Cash from Investing Activities | -179.09 | 54.75 | 37.96 | 41.57 | 7.46 |
Uses of Funds
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
---|---|---|---|---|---|
Issuance (Repurchase) of Capital Stock | 6.77 | -5.95 | 7.63 | 1.27 | 1.11 |
Issuance (Repayment) of Debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Increase (Decrease) Short-Term Debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Payment of Dividends & Other Distributions | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Financing Activities | 264.61 | 10.11 | -0.75 | -0.32 | -0.22 |
Net Cash from Financing Activities | 271.38 | 4.16 | 6.88 | 0.95 | 0.89 |
Effect of Exchange Rate Changes | -0.03 | -0.26 | 0.00 | 0.00 | 0.00 |
Net Change In Cash & Equivalents | 18.88 | 10.26 | -2.75 | 20.74 | -16.40 |
Cash at Beginning of Period | 36.63 | 26.37 | 29.12 | 8.38 | 24.78 |
Cash at End of Period | 55.52 | 36.63 | 26.37 | 29.12 | 8.38 |
Diluted Net EPS | -0.91 | -0.90 | -0.71 | -0.54 | -0.36 |
Fiscal Year End for Viking Therapeutics, Inc falls in the month of December.
All data in Millions except Per Share data.
Cash Flow From Operations, Investments & Financial Activities
6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | |
---|---|---|---|---|---|
Cash Flow From Operations, Investments & Financial Activities |
|||||
Net Income (Loss) | -49.61 | -27.36 | -85.90 | -61.29 | -38.76 |
Depreciation/Amortization & Depletion | -8.06 | -2.72 | -7.82 | -5.22 | -2.15 |
Net Change from Assets/Liabilities | 7.94 | 15.95 | 3.55 | -1.93 | -3.38 |
Net Cash from Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Operating Activities | 15.08 | 7.99 | 16.79 | 12.70 | 8.21 |
Net Cash From Operating Activities | -34.65 | -6.13 | -73.38 | -55.74 | -36.08 |
Property & Equipment | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Acquisition/ Disposition of Subsidiaries | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Investments | -585.85 | -459.79 | -179.09 | -214.82 | -202.29 |
Other Investing Activities | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Net Cash from Investing Activities | -585.85 | -459.79 | -179.09 | -214.82 | -202.29 |
Uses of Funds
6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | |
---|---|---|---|---|---|
Issuance (Repurchase) of Capital Stock | 7.29 | 4.36 | 6.77 | 6.58 | 6.58 |
Issuance (Repayment) of Debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Increase (Decrease) Short-Term Debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Payment of Dividends & Other Distributions | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Financing Activities | 601.65 | 601.68 | 264.61 | 264.61 | 264.68 |
Net Cash from Financing Activities | 608.94 | 606.04 | 271.38 | 271.19 | 271.26 |
Effect of Exchange Rate Changes | -0.05 | -0.05 | -0.03 | -0.08 | -0.01 |
Net Change In Cash & Equivalents | -11.60 | 140.06 | 18.88 | 0.55 | 32.89 |
Cash at Beginning of Period | 55.52 | 55.52 | 36.63 | 36.63 | 36.63 |
Cash at End of Period | 43.92 | 195.58 | 55.52 | 37.19 | 69.52 |
Diluted Net EPS | -0.20 | -0.26 | -0.24 | -0.23 | -0.19 |